Home/Pipeline/Lung (NSCLC) PD-L1

Lung (NSCLC) PD-L1

Non-Small Cell Lung Cancer

CommercialActive

Key Facts

Indication

Non-Small Cell Lung Cancer

Phase

Commercial

Status

Active

Company

Mindpeak

About Mindpeak

Mindpeak is a Hamburg-based AI/ML company operating at the intersection of digital pathology and precision medicine. It has developed a suite of CE-marked, deep learning-based software products that automate the analysis of immunohistochemistry (IHC) and H&E-stained tissue samples, primarily for oncology biomarkers like PD-L1, HER2, and Ki-67. The company's value proposition centers on '0-click' integration, offering both standalone and deeply embedded solutions within partner laboratory information systems to improve pathologist efficiency and diagnostic consistency. Mindpeak appears to be in a commercial, revenue-generating stage, serving diagnostic labs, hospitals, and research institutions.

View full company profile

Therapeutic Areas

Oncology Dermatology

Other Non-Small Cell Lung Cancer Drugs

Drug	Company	Phase	Status
CM24	Purple Biotech	Phase 2	Active
Pepinemab (VX15/2503)	Vaccinex	Phase 1b/2	Completed
GC-001	Genocury Biotech	Preclinical	Active
Immunomodulator Platform	OmniCyte	Research	Active
VisAcT (18F-AraG) Imaging in NSCLC	CellSight Technologies	Phase 2	Active
VNX-208	Vironexis Biotherapeutics	Preclinical	Active
AIC100	AffyImmune Therapeutics	Pre-clinical/Planned	Active
Tiragolumab	Chugai Pharmaceutical	Phase III	Active
SHR-1701	Jiangsu Hengrui Medicine	Phase II/III	Active
Acasunlimab (DuoBody-PD-L1x4-1BB)	Genmab	Phase 2/3	Active
VAC2	Lineage Cell Therapeutics	Phase 1	Active